What is chronic eosinophilic leukaemia?
Chronic eosinophilic leukaemia (CEL) is a rare blood cancer where the bone marrow produces an excess of eosinophils. Eosinophils are a type of white blood cell. In normal amounts they help fight parasites and take part in allergic reactions. When there are far too many of them for a long time, they can enter tissues and damage organs, especially the heart, lungs, skin, nerves and gut.
CEL is one of the myeloproliferative neoplasms, a group of chronic blood cancers in which the marrow overproduces one or more types of blood cell. What sets CEL apart is that the excess eosinophils come from an abnormal (clonal) population of marrow cells, rather than being a reaction to another problem such as an allergy, an infection or a drug.
A high eosinophil count is common, and most cases have a non-cancerous cause. CEL is diagnosed only after doctors have ruled out these other causes and found evidence that the marrow itself is abnormal. Modern genetic tests now separate CEL from related conditions, some of which respond extremely well to targeted tablets (Shomali and Gotlib, 2024).
CEL is often a serious illness. It tends to affect older adults, can progress to acute leukaemia, and has limited treatment options. A stem cell transplant is the only treatment that may cure it, but it is not suitable for everyone (Costa et al., 2025).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Myeloproliferative neoplasm with clonal eosinophilia |
| Blood finding | Eosinophil count persistently at least 1.5 x 10^9/L |
| How common | Rare; true frequency unknown |
| Typical age | Usually older adults |
| Main risks | Organ damage from eosinophils; progression to acute leukaemia |
| Main genetic changes | No single driver; changes such as STAT5B, SF3B1, ASXL1 and others may be found |
| Main treatments | Steroids, hydroxyurea, interferon-alpha, chemotherapy, stem cell transplant |
| Curative option | Allogeneic stem cell transplant for suitable patients |
| Outlook | Often guarded; varies widely |
2. Types
Disorders with high eosinophil counts
The modern classification groups eosinophil disorders according to their cause and genetics (Shomali and Gotlib, 2024).
| Condition | Cause | Key point |
|---|---|---|
| Reactive (secondary) eosinophilia | Allergy, asthma, parasites, drugs, other cancers | The most common cause; treat the underlying problem |
| Fusion-driven myeloid/lymphoid neoplasms with eosinophilia (MLN-eo-TK) | Fusions involving PDGFRA, PDGFRB, FGFR1, JAK2 or others | Some respond dramatically to targeted drugs such as imatinib |
| Chronic eosinophilic leukaemia (CEL) | Clonal marrow disorder without these fusions | Limited treatment options |
| Lymphocyte-variant hypereosinophilia | An abnormal T-cell population drives eosinophil production | Usually treated with steroids |
| Idiopathic hypereosinophilic syndrome (HES) | No cause found after full testing | Diagnosis of exclusion |
Why the gene fusion test matters
People whose cells carry a PDGFRA or PDGFRB rearrangement usually respond very well to imatinib, often at low doses (Shomali and Gotlib, 2024). In the past, many of these patients would have been diagnosed with CEL. Today they are classified separately. The term CEL (formerly “CEL, not otherwise specified”) is now reserved for cases without these targetable fusions.
CEL compared with idiopathic HES
| Feature | CEL | Idiopathic HES |
|---|---|---|
| Evidence of clonality | Present (genetic changes or increased blasts) | Absent |
| Bone marrow | Abnormal features | Increased eosinophils only |
| Risk of acute leukaemia | Present | Low |
| First-line treatment | Varies; often cytoreductive drugs | Steroids |
Genetic testing has shown that some patients previously diagnosed with idiopathic HES in fact have a clonal disorder (Costa et al., 2025).
3. Causes and risk factors
The cause of CEL is not known. It arises from acquired genetic changes in the bone marrow stem cells.
| Factor | Notes |
|---|---|
| Age | Mostly older adults |
| Acquired gene changes | For example STAT5B N642H, SF3B1, ASXL1, TET2 |
| Inherited factors | No inherited cause known |
| Lifestyle or environment | No established link |
The STAT5B N642H mutation
Researchers found a specific mutation, STAT5B N642H, in about 1.6% of people referred for investigation of a high eosinophil count. People with this mutation alone, or with an additional SF3B1 mutation, had much longer survival than those with other additional mutations (Cross et al., 2019). The researchers suggested that cases previously labelled HES with this mutation are better described as CEL.
4. How does it look
In the blood and marrow
| Test | Typical finding |
|---|---|
| Full blood count | High eosinophil count; may also show anaemia or low platelets |
| Blood film | Eosinophils, sometimes with abnormal shapes; blasts may be present |
| Bone marrow biopsy | Increased cellularity, many eosinophils, sometimes abnormal maturation or increased blasts |
| Marrow fibrosis | Sometimes present |
| Chromosome and gene tests | Show clonal changes |
Organ involvement
| Organ | Possible effects |
|---|---|
| Heart | Inflammation, scarring of the heart lining, clots, heart failure |
| Lungs | Cough, wheeze, infiltrates on scans |
| Skin | Itching, rashes, swelling |
| Nerves | Numbness, tingling, weakness |
| Gut | Abdominal pain, diarrhoea |
| Spleen and liver | Enlargement |
| Blood vessels | Clots in veins or arteries |
5. Symptoms
Some people have no symptoms, and the condition is found on a routine blood test.
Common symptoms
- Tiredness
- Fever and night sweats
- Itching and skin rashes
- Cough or breathlessness
- Muscle aches
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Swelling of the face, lips or hands | Angioedema |
| Chest pain, palpitations, ankle swelling | Heart involvement |
| Diarrhoea or abdominal pain | Gut involvement |
| Numbness or tingling in hands and feet | Nerve involvement |
| Fullness under the left ribs | Enlarged spleen |
| Sudden weakness or speech problems | Stroke from a clot (rare) |
When to seek urgent help
Seek urgent medical help for chest pain, severe breathlessness, sudden weakness or speech difficulty, or swelling of the throat or tongue.
6. Diagnosis
Diagnosis is a step-by-step process.
| Step | Tests |
|---|---|
| 1. Confirm high eosinophils | Repeat blood counts over several weeks |
| 2. Exclude reactive causes | Allergy and asthma review, stool and blood tests for parasites, medication review, tests for other cancers |
| 3. Look for targetable fusions | FISH or molecular tests for PDGFRA, PDGFRB, FGFR1, JAK2 and others |
| 4. Look for clonality | Bone marrow biopsy, chromosome analysis, gene panel testing |
| 5. Check for abnormal T cells | Flow cytometry and T-cell receptor studies |
| 6. Assess organ damage | Heart scan (echocardiogram, cardiac MRI), troponin, lung function, chest imaging |
The diagnosis relies on combining blood and marrow morphology, cytogenetics, FISH, molecular testing and flow cytometry (Shomali and Gotlib, 2024).
Risk assessment
There is no formal staging system. Doctors consider:
- The eosinophil count and how fast it is rising
- Whether organs are damaged
- The genetic changes present
- The proportion of blasts in the blood and marrow
- The patient’s age and fitness
7. Treatment
The main goals are to lower the eosinophil count, protect organs and, where possible, prevent progression. Treatment is chosen by a haematologist experienced in these disorders.
Treatment options
| Treatment | Role |
|---|---|
| Watchful waiting | For mild eosinophilia without symptoms or organ damage, with close monitoring |
| Corticosteroids (prednisolone) | Rapid reduction of eosinophils; often used first in emergencies |
| Hydroxyurea | Oral drug that lowers blood counts |
| Interferon-alpha | Injection that can control eosinophils |
| Imatinib | Very effective for PDGFRA/PDGFRB fusions; limited benefit in CEL without these |
| Mepolizumab and other anti-IL-5 drugs | Approved for idiopathic HES; role in CEL under study |
| Chemotherapy | For aggressive disease or progression to acute leukaemia |
| Allogeneic stem cell transplant | The only potentially curative treatment |
Steroids, cytoreductive drugs and immune-modifying treatments often give only partial and temporary responses in CEL and may cause significant side effects (Costa et al., 2025).
Why treatment is difficult
Unlike the fusion-driven disorders, CEL has no single genetic target that a drug can switch off. Each patient’s disease may carry a different mix of mutations, which makes it hard to design trials. Because the condition is so rare, most information comes from small case series. A 2026 report describing two patients highlighted how limited the guidance remains for people without a targetable mutation (Varada et al., 2026).
In practice, doctors often start with drugs that lower the eosinophil count and then consider transplant early in fit patients with high-risk features. Newer targeted drugs, including antibodies against IL-5 and its receptor, are being tested in clinical trials (Shomali and Gotlib, 2024).
Stem cell transplant
| Aspect | Details |
|---|---|
| Who may be suitable | Fitter patients, usually with a matched donor |
| Purpose | Replace the abnormal marrow with donor cells |
| Limits | Many patients are older or have other illnesses |
| Outcome | About a third of patients alive at five years after transplant |
Emergency treatment
| Situation | Treatment |
|---|---|
| Very high eosinophil count with organ damage | High-dose steroids immediately |
| Heart involvement | Steroids, heart medicines, anticoagulants for clots |
| Possible parasite exposure | Ivermectin may be given before steroids to prevent worsening of a hidden parasitic infection |
Side effects
| Treatment | Possible side effects |
|---|---|
| Long-term steroids | Weight gain, high blood sugar, bone thinning, mood changes, infections |
| Hydroxyurea | Low blood counts, mouth ulcers, skin changes |
| Interferon-alpha | Flu-like symptoms, low mood, tiredness |
| Imatinib | Fluid retention, nausea, muscle cramps |
| Stem cell transplant | Infection, graft-versus-host disease, organ damage |
8. Outlook (prognosis)
| Factor | Effect |
|---|---|
| Targetable fusion found | Excellent response to imatinib (these patients are no longer classified as CEL) |
| STAT5B N642H alone or with SF3B1 | Longer survival in one study |
| Other high-risk mutations | Shorter survival |
| Heart involvement | Poorer outlook |
| Progression to acute leukaemia | Poor outlook |
| Suitability for transplant | Offers the only chance of cure |
CEL generally has a poor prognosis, and even after transplant only about one in three patients is alive at five years (Costa et al., 2025). In the STAT5B study, median survival was about 65 months for the favourable group and 14 months for those with other additional mutations (Cross et al., 2019). The course varies widely, and some people live with stable disease for a long time.
9. Follow-up
| Check | Purpose |
|---|---|
| Blood counts | Every few weeks at first, then less often |
| Heart assessment | Echocardiogram or cardiac MRI and troponin at intervals |
| Bone marrow tests | If counts change or progression is suspected |
| Side effect monitoring | Blood sugar, bone density and blood pressure on steroids |
| Transplant follow-up | Long-term, at the transplant centre |
10. Living with chronic eosinophilic leukaemia
- Take medicines exactly as prescribed, and do not stop steroids suddenly
- Report chest pain, breathlessness or swelling without delay
- Protect your bones if you take steroids, with calcium, vitamin D and exercise
- Avoid infections where you can, and keep vaccinations up to date as advised
- Tell other doctors you have CEL and which drugs you take
- Ask about clinical trials, as new treatments are being studied
- Seek support from blood cancer charities and patient groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Does a high eosinophil count mean leukaemia? | Usually not; allergies, asthma, parasites and medicines are far more common causes |
| Is CEL the same as hypereosinophilic syndrome? | No; CEL shows evidence of a clonal marrow disorder, while idiopathic HES does not |
| Will imatinib work for me? | It works best when a PDGFRA or PDGFRB fusion is present |
| Can CEL be cured? | Only a stem cell transplant offers a chance of cure |
| Can it turn into acute leukaemia? | Yes, in some patients |
| Is it inherited? | No |
| How often will I need blood tests? | Often at first, then less frequently once the count is stable |
| Why are heart tests needed? | Eosinophils can damage the heart, sometimes without symptoms |
12. Questions to ask your care team
- Have reactive causes of my eosinophilia been ruled out?
- Have I been tested for PDGFRA, PDGFRB, FGFR1 and JAK2 changes?
- What genetic changes were found, and what do they mean?
- Are any of my organs affected?
- Which treatment do you recommend, and what are its side effects?
- Am I a candidate for a stem cell transplant?
- Are there clinical trials I could join?
Resources
- Costa, A., Scalzulli, E. and Breccia, M. (2025) ‘Chronic eosinophilic leukaemia-not otherwise specified: clinical features, genomic insight and therapeutic strategies’, British Journal of Haematology, 206(1), pp. 44-60.
- Cross, N.C.P. et al. (2019) ‘Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia’, Leukemia, 33(2), pp. 415-425.
- Shomali, W. and Gotlib, J. (2024) ‘World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management’, American Journal of Hematology, 99(5), pp. 946-968.
- Varada, N.L. et al. (2026) ‘Chronic eosinophilic leukemia not otherwise specified: a case series’, Journal of Hematology, 15(3), pp. 162-168.
- National Cancer Institute (2026) Myeloproliferative Neoplasms Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloproliferative/hp/myeloproliferative-neoplasms-treatment (Accessed: October 2026).
Prepared by the editorial team, October 2026.